Antiva Biosciences, which is developing therapies to treat lesions that cause cervical cancer, has raised $22m in a series C round led by the venture capital arm of EMS.
Brace Pharma Capital, the strategic investment arm of pharmaceutical company EMS, led a $22m series C round for US-based human papilloma virus (HPV) treatment developer Antiva Biosciences yesterday.
The round also featured Osage University Partners, a venture capital firm that focuses on university spinouts, as well as Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real Estate Equities, NS Investment, Canaan Partners and Sofinnova Ventures.
Founded in 2012 as Hera Therapeutics, Antiva is working on topical…
